Can Novo Nordisk's blockbuster weight loss drug and other GLP-1s also work in NASH? The answer is complicated
Back in 2020, before semaglutide became a household name — before it was even approved to treat obesity — Novo Nordisk quietly notched a breakthrough therapy designation in a hot indication: nonalcoholic steatohepatitis, or NASH.
Three years later, the GLP-1 receptor agonist has emerged as one of the “most recognized and anticipated” new treatments for a disease that’s been dubbed a silent killer and defeated multiple experimental drugs. Novo is still recruiting NASH patients with fibrosis in a 1200-patient Phase IIIa study, with data not expected until 2028.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
